Souhaitez-vous accéder aux communiqués récents ?

Austin, TX, USA, June 29, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “Hematologic Malignancies Testing Market Size, Trends and Insights By Product...

Austin, TX, USA, June 19, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “Automated Liquid Handling Systems Market Size, Trends and Insights By Type...

WATERTOWN, Mass. and CINCINNATI, June 18, 2026 (GLOBE NEWSWIRE) -- Constantiam Biosciences and Cincinnati Children's today announced a strategic collaboration through an exclusive option for future...

Austin, TX, USA, May 05, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “Targeted DNA RNA Sequencing Market Size, Trends and Insights By Technology (NGS,...

Transaction is Hopewell’s first commercial license of proprietary lipid nanoparticles (LNPs)Hopewell’s LNPs are the preferred delivery solution for the cancer vaccine technology that Foxcroft licensed...

Castle announced the publication of two new studies related to its DecisionDx-SCC test for patients with high-risk cutaneous squamous cell carcinoma.

Castle will present new data aimed at enhancing the clinical management of patients with cutaneous melanoma and uveal melanoma at ASCO 2025.

Castle presented new data from the first independent validation of the recently published COOG2.1 study by Harbour et al. at ARVO 2025.

Castle announced the publication of a new study demonstrating DecisionDx-Melanoma outperforms AJCC staging and the CP-GEP test.

Tome Biosciences launches with over $200 million in funding to advance programmable genomic integration (PGI).